Lausanne, Geneva: Method to enhance Factor VIII production

Licensing opportunity

Researchers at the University of Geneva, University Hospitals of Geneva, and University Hospital of Lausanne have jointly developed a method to enhance in vitro secretion of Factor VIII, an essential blood clotting factor.

Mutations in the gene for producing Factor VIII lead to the blood clotting disorder Haemophilia A. Several drugs based on recombinant factor VIII are currently marketed, with annual sales of over $3 billion.

The technology could be applied to improve manufacturing process for Factor VIII, reducing costs. It is compatible with most currently used production systems in mammalian cells.

Patent status: Priority application 61/182,189 filed on 29 May 2009